References
- Smith A. Screening for drug discovery: the leading question. Nature 2002; 418: 453–460.
- Heemskerk J, Tobin AJ, Ravina B. From Chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nature Neurosci 2002; (Suppl 5), 1027–1029.
- Heemskerk J, Tobin AJ, Bain LJ. Teaching old drugs new tricks. Trends Neurosci 2002; 25: 494–496.
- Kosik KS, Ahn J, Stein R, Yeh LA. Discovery of compounds that will prevent tau pathology. J Mol Neurosci 2002; 19: 261–266.
- Andreassi C, Jarecki J, Zhou J et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10: 2841–2849.
- Ghadge GD, Lee JP, Bindokas VP et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: mole- cular mechanisms of neuronal death and protection. J Neurosci 1997; 17: 8756–8766.
- Finkelstein R, Miller T, Baughman R. The challenge of transla- tional research: a perspective from the NINDS. Nature Neurosci 2002; (Suppl 5): 1029–1030.